Helical and Static-port Tomotherapy Using the Newly-developed Dynamic Jaws Technology for Lung Cancer. (October 2015)

• Record Type: Journal Article
• Authors: Manabe, Yoshihiko; Shibamoto, Yuta; Sugie, Chikao; Hayashi, Akihiro; Murai, Taro; Yanagi, Takeshi
• Is Part Of: Technology in cancer research & treatment. Volume 14:Number 5(2015:Oct.)
• Page Start: 583
• Page End: 591
• Publication Date: 2015-10
• Subjects: Dynamic jaws -- Lung cancer -- Static port -- Tomotherapy.; Oncology -- Periodicals; Cancer -- Diagnosis -- Periodicals; Cancer -- Treatment -- Technological innovations -- Periodicals; 616.994
• DOI: 10.7785/tcrtexpress.2013.600280
• Languages: English
• ISSNs: 1533-0346

Abstract

With the newly developed dynamic jaws technology, radiation dose for the cranio-caudal edges of a target can be lowered in the treatment with tomotherapy. We compared dynamic-jaw- and fixed-jaw-mode plans for lung cancer. In 35 patients, four plans using the 2.5-cm dynamic-, 2.5-cm fixed-, 5.0-cm dynamic-, and 5.0-cm fixed-jaw modes were generated. For 10 patients with upper lobe stage I lung cancer, the helical tomotherapy mode was used. Fifty-six Gy in 8 fractions was prescribed as a minimum coverage dose for 95% of the target (D95%). For 25 patients with locally advanced lung cancer, plans using four static ports (TomoDirect® mode) were made. Sixty Gy in 30 daily fractions for the primary tumor and swollen lymph nodes and 51 Gy in 30 fractions for prophylactic lymph node areas were prescribed as median doses. The mean conformity index of the planning target volume were similar among the four plans. The mean V5 Gy of the lung for 2.5-cm dynamic-, 2.5-cm fixed-, 5.0-cm dynamic-, and 5.0-cm fixed-jaw mode plans were 18.5%, 21.8%, 20.1%, and 29.4%, respectively ( p < 0.0001), for patients with stage I lung cancer, and 37.3%, 38.7%, 40.4%, and 44.0%, respectively ( p < 0.0001), for patients with locally advanced lung cancer. The mean V5 Gy of the whole body was 1, 826, 2, 143, 1, 983, and 2, 939 ml, respectively ( p < 0.0001), for patients with stage I lung cancer and 4, 849, 5, 197, 5, 220, and 6, 154 ml, respectively ( p < 0.0001), for patients with locally advanced lung cancer. Treatment time was reduced by 21-39% in 5.0-cm dynamic-jaw plans compared to 2.5-cm plans. Regarding dose distribution, 2.5-cm dynamic-jaw plans were the best, and 5.0-cm dynamic-jaw plans were comparable to 2.5-cm fixed-jaw plans with shorter treatment times. The dynamic-jaw mode should be used instead of the conventional fixed-jaw mode in tomotherapy for lung cancer.